2. Competitive Landscape  Advances in applied drug discovery, peptide mimicry, chemotherapeutic strategy, and biointellect are fueling the need for rapid innovation and evolution within the drug delivery sector.  The ability to cost effectively develop new biologically active agents with enhanced therapeutic capabilities and viable routes of administration may very well determine the success or failure of new drugs rather than the validity of therapy.  Global revenues from new drug delivery technologies are projected to exceed 218 billion dollars by 2018. Pharmaceutical Industry

3. 10 Areas of Focus 1.Improved efficacy 2.Reduced side effects 3.Continuous dosing (sustained release) 4.Reduced pain and discomfort from administration 5.Increased ease of use 6.Increased use compliance 7.Improved mobility 8.Decreased involvement of healthcare workers 9.Improved safety for healthcare workers 10.Reduced environmental impact * Source: Product Genesis, 2004

4. Pharmaceutical Industry Drug Delivery Methods  Topical – risk of systemic side effects is reduced  Inhalation – can be absorbed quickly, and act both locally and systemically  Injection – encompasses intravenous (IV), intramuscular (IM), and subcutaneous (SC)  Oral – most convenient and cost effective

5. Pharmaceutical Industry The Challenge Deliver both existing and emerging therapeutic agents in a manner that lowers costs while improving viability and value to patients, healthcare workers, and the overall healthcare system.

7. Tamarisk’s Patented Oral Delivery System  Oral disposition of therapeutic agents is the most cost effective, patient friendly, and preferred dosing route of pharmaceutical scientists and physicians.  Tamarisk Technologies Group has developed a patented drug transport system that nanoencapsulates therapeutic agents for oral administration.  Unlike any other oral drug delivery technology, this method provides the greatest potential for enhanced: 1.Bioavailability 2.Targeted disposition 3.Extended Half-Life The Solution

8. Tamarisk’s Patented Oral Delivery System 100% resistant to gastric and intestinal disintegration Manipulates the body’s natural lipid uptake mechanism to gain entry into the bloodstream Releases a therapeutic payload within 15 minutes of reaching systemic circulation Provides up to 95% bioavailability of therapeutic payload Contains all-natural organic Biopolymers And… The Solution

9. Tamarisk’s Patented Oral Delivery System Eliminates use of needle and syringe

10. Overview  Founded in 2008  Privately held technology development company  Reorganized as Tamarisk Technologies Group in 2014  Offering Serum Specific, Tissue Specific, and Extended Release Technologies About Us

11. Who We Are Dean Crowell | Executive Director John Connell | Chairman/Director of Corp Development A.T. Snoots, II | Director of Operations Darrell Turner | Director of Finance Daniel DeBrouse | Inventor/CSO About Us

12. Objective Our ongoing objective at Tamarisk is to apply the natural macroscopic and microscopic symbiosis established in creation to laboratory and commercial scale production of therapeutic agents, drug transport systems and "green technologies". United in our endeavor, the Tamarisk team is dedicated to developing technology for the future and delivering viable solutions that will make the world a better place both now and for generations to come.

13. Meeting the Demand Addressing Pharma’s 10 Areas of Focus 1.Improved efficacy: Greater bioavailability, tissue specific delivery, and extended serum release delivery will make therapeutic agents much more effective while reducing the therapeutic dose. 2.Reduced Toxicity: No upset stomachs or nausea; caregivers able to target specific problems with precision rather than broad spectrum dosing. 3.Extended Release: Sustained release and enhanced bioavailability over a period of days. Oral delivery of what was formerly infused by intravenous drip or by intravenous pump. Tamarisk’s Oral Drug Delivery

14. Meeting the Demand Addressing Pharma’s 10 Areas of Focus (continued) 4.Reduced pain from administration: Oral delivery of what was formerly delivered by injection. Gastro-intestinal distresses are eliminated. 4.Increased ease of use: Eliminates mechanical devices, needles, IVs, pumps etc. 5.Increased use compliance: Oral delivery encourages greater compliance. 4.Improved mobility: No bulky or cumbersome devices - only a bottle of capsules. Tamarisk’s Oral Drug Delivery

15. Meeting the Demand Addressing Pharma’s 10 Areas of Focus (continued) 8.Decreased involvement of healthcare workers: No assistance needed with taking oral therapeutics. 9.Improved safety for healthcare workers: Oral ingestion means no needles, eliminating the potential for needle pricks and or bloodborne pathogens. 10.Reduced environmental impact (elimination of CFC’s): No CFC’s are used in the drug delivery system or processes. Tamarisk’s Oral Drug Delivery

16. 3 System Components Currently, there are three delivery components which may be used independently or synergistically: 1.Serum Specific – within 15 minutes delivers up to 95% of the therapeutic agent directly into the bloodstream. 2.Tissue Specific – targeted delivery to any tissue in the body. 3.Extended Serum Release – releases dosage at predetermined intervals over an extended time. Tamarisk’s Oral Drug Delivery

17. 12 Key Benefits 1.Innovative encapsulation process 2.Minimal processing required 3.Less expensive than traditional microencapsulation 4.Any therapeutic agent may be encapsulated, including vaccines and chemotherapeutics 5.Nanoencapsulate is 100% resistant to gastric and intestinal disintegration 6.Up to 95% of a therapeutic agent may be delivered directly to the bloodstream Tamarisk’s Oral Drug Delivery

18. 12 Key Benefits (continued) 7.100% disintegration may be achieved within 15 minutes after entering the bloodstream 8.A single capsule can provide therapy for an extended period of time 9.Delivers therapeutic agent to a targeted diseased area within the body 10.Less therapeutic agent is required for maximum medicinal benefit 11.Zero toxicity 12.100% all-natural and solvent free Tamarisk’s Oral Drug Delivery

19.  Blueberry Extract  Prune Extract  Spinach Extract  Raspberry Extract  Cranberry Extract  Bilberry Extract  Folic Acid  Resveratrol  Insulin  Alpha Lipoic Acid  DHA  Selenium  Astaxanthin  Lutein  Lycopene  Biotin  Chromium Picolinate  PYY 3-36  Pegylated Interferon Proof of Benefits Therapeutic agents successfully encapsulated :  Vitamin B1  Vitamin B2  Niacin  Vitamin B12  Vitamin B6  Indole-3-Carbinol  Zinc Aspartate  Vitamin E Tamarisk’s Oral Drug Delivery

20.  Vitamin C – single dose up to 27,000 mg with no gastrointestinal side effects  COQ10 – demonstrated 73-95% bioavailability  Pregnenolone – resulted to be more effective than hormone shots for female patients.  Magnesium – 50mg doses shown to stabilize blood pressure at 120/80 in hypertensive patients and hold for 32 hours. Tamarisk’s Oral Drug Delivery Proof of Benefits Therapeutic agents successfully encapsulated :

21.  Ceftriaxone Sodium (Rocephrin) - showed a 73% bioavailability in rabbits  Insulin – 1 unit administered to diabetic rats  Methylene Blue - exposed to gastric fluid, intestinal fluid, and human serum in vitro. Zero disintegration occurred with both gastric and intestinal fluids. 100% disintegration was achieved within 15 minutes after exposure to bloodstream with 100% of dye released. Tamarisk’s Oral Drug Delivery Proof of Benefits Therapeutic agents successfully encapsulated :

22. Clinical Work Syracuse University Insulin encapsulated and diabetic rats were dosed with 1 unit (2008). Tamarisk Technologies Pre-clinical trial conducted with CoQ10 showed 73-95% bioavailability (2010). MERCK & Company Microparticles containing resveratrol, supplied by Tamarisk Technologies LLC (2010). Tamarisk Technologies Insulin encapsulated and diabetic rats were dosed with 1 unit (2012). Tamarisk’s Oral Drug Delivery

23. In Conclusion Tamarisk’s SSNe Oral Drug Delivery  New delivery technology is extremely critical.  Many complex medications require a method of specialized delivery.  Pharmaceutical manufacturers must have an effective oral therapeutic delivery system that meets the challenging needs of the market.  The innovative oral therapeutic delivery system developed by Tamarisk Technologies can potentially address all therapeutic delivery challenges.

24. In Conclusion Tamarisk’s SSNe Oral Drug Delivery  Tamarisk’s oral therapeutic delivery system surpasses all current and anticipated delivery technologies and provides the greatest value for both stakeholders and end users alike.  Tamarisk’s technology opens new avenues of development for new and drug technologies in the 21 st century.

25. Opportunity Tamarisk's unique delivery platform is ready to be entrusted to an effective global leader in the Healthcare industry who's expertise and core values may be combined with our technology to In Conclusion provide the next generation of leading edge therapeutic products. If your company is looking for the most effective oral delivery system for it's existing pharmaceutical therapies or those in it's pipeline, it's time to consider a new solution. It's time to consider Tamarisk. There's no better time than now for a technology with so much potential to make the world a better place both for us now and for generations to come.

26. Opportunity Tamarisk is now welcoming partnership, collaboration, licensing, and purchase proposals for this patented delivery technology. For more information or to request a copy of this full length presentation, a Non-Disclosure Agreement is mandatory. Contact us at In Conclusion info@tamarisktechnologiesgroup.com phone 702.516.6451 fax 702.442.1954 www.tamarisktechgroup.com

27. Note: No part of this presentation may be copied, modified, printed, or presented without the author’s permission. 2014 © Tamarisk Technologies Group, LLC. All rights reserved.